Back to catalogue
№ 177 25 filings · 2021-08-31 → 2026-06-25

DIACEUTICS PLC

DXRX
Health Care Share price 204p Market cap £173m Overall fit 560 /1000

Fair-price scaling data platform with clear operating leverage and modest AI-adjacency via proprietary pharma-diagnostic dataset; discount for indirect AI exposure, small-cap fragility, and cash-conversion concerns keeps it out of the top band.

Fair value range 170p–220p Mid case · £165m
Absolute upside -4.6% vs current market cap
Conviction 3/5 confidence in undervalued call
Supports the call
  • Clean disclosure with ARR/NRR/order-book KPIs
  • Multiple valuation methods converge on £145-190m
  • 5-year revenue CAGR ~25% with visible 2025 margin inflection
Limits the call
  • FY26 25% growth guide only Q1-validated (15% CC)
  • Working capital deterioration and thin £7.3m cash cushion
Methodology

Blended EV/Revenue and EV/Adj.EBITDA on FY26E, ARR cross-check

In one line · bull case

Scaled specialist data/AI platform for pharma diagnostic commercialisation with proven operating leverage now visible in the P&L, available at ~3x revenue with a credible 25% FY26 growth setup.

In one line · biggest risk

FY26 growth disappoints or working capital stretches further, forcing a dilutive equity raise off a thin £7m cash base.

Drivers
AI beneficiary 50 /100
Proprietary pharma-diagnostic data + AI-enabled DXRX platform benefit as pharma commercialization goes agentic, but AI is enabler not primary revenue driver.
Operating leverage 75 /100
82% gross margin, mostly-fixed £21m employee cost — 20% revenue growth delivered 80% adj. EBITDA growth in FY25.
Earnings vs expectations 60 /100
Pattern of beats FY22-24; FY25 revenue small miss vs. consensus but EBITDA beat.
Growth momentum 70 /100
Decelerating (39%→24% CC) but still solid; FY26 guide 25% supported by 56% order-book growth.
Moat 55 /100
Proprietary lab-network data + 18/top-20 pharma relationships + platform switching costs; not yet dominant.
Earnings quality 55 /100
Working-capital stretch: cash -42% YoY despite reported profitability; heavy intangible capitalisation.
Management quality 65 /100
Founder-led with orderly CEO transition; disciplined investment cycle delivered as promised.
Cyclicality 30 /100
Pharma R&D and commercialisation spend is moderately cyclical; recurring/order-book mix dampens.
Leverage 10 /100
Net cash £7.3m, no debt, £2m undrawn overdraft — but cash cushion is thin.
Value-trap signals · 3
  • Cash conversion weak — cash fell 42% despite return to profit
  • Revenue growth decelerating and FY25 revenue missed consensus
  • Customer concentration (top customer 18% of revenue; 93% US exposure)

Diaceutics PLC (DXRX) — Investment Research Note

Executive summary

Diaceutics is a specialist data/analytics and technology platform (DXRX) that helps global pharma and biotech identify eligible patients for precision-medicine therapies via a network of ~900+ diagnostic labs, proprietary patient-testing data, and increasingly-recurring subscription solutions. Across FY21–FY25 the business scaled from £13.9m to £38.4m of revenue (3-year CAGR ~25%), returned to profitability in 2025 (PBT £0.3m; adj. EBITDA £7.6m at a 20% margin), and grew ARR to £20.0m with a £38.9m order book. The single most important valuation point today is whether the visible operating leverage of the platform model — 80% adj. EBITDA growth on 20% revenue growth in 2025 — persists into the 25%-growth outlook management has set for FY26 2026-05 Final Results; 2026-01 FY25 trading update.

Fair value estimate

Fair value range: 170p – 220p per share (implied market cap: £144m – £187m) Mid-point: ~195p / ~£165m (~24% upside vs. current 158p / £124.3m)

Methodology: blended EV/Revenue and EV/Adj. EBITDA multiples on FY26 estimates, sanity-checked against ARR multiple.

Key assumptions:

  • FY26 revenue: £48m (25% growth per management guidance in Jan-2026 trading update — Q1 in-line at 15% CC vs. tough comp).
  • FY26 adj. EBITDA: £11–12m (23–25% margin, extending the trajectory 13% → 20% seen 2024→2025).
  • Central case: 3.5–4.5x FY26 EV/Revenue (~SaaS-lite specialist data multiple, adjusted for AIM discount, small-cap illiquidity, and customer concentration); 13–16x FY26 EV/Adj. EBITDA.
  • ARR cross-check: 6–8x forward ARR (£20m → 2026 ARR likely ~£24m) = £144–192m EV.
  • Add net cash £7.3m; no financial debt.

Downside sanity-check: on FY25 actuals (£38.4m revenue, £7.6m adj. EBITDA) at 3x revenue / 15x adj. EBITDA the business is worth £115–120m — approximately today's market cap, so the current price prices in the delivered result but attributes little to the FY26 guidance.

Absolute upside vs. £124.3m cap: ~24% at mid; +16% to +50% at bounds.

Sector context

  • ICB classification: Health Care (Health Care Providers/Health Care Technology). Confirmed appropriate — Diaceutics sits between data-analytics (Trak Health-Tech) and specialist pharma services.
  • Quality/growth/leverage profile: above typical UK healthcare-services peers on gross margin (82%) and recurring-revenue mix; in line on growth rate for a scaling data platform; below on scale (£38m revenue is small vs. sector).
  • Comparable listed peers: Ideagen (private now, previously AIM vertical SaaS); Craneware (AIM, healthcare data/analytics — good comp on multiple); Veeva Systems (US, larger and more expensive pharma cloud); Definiens/Concert Genetics (private). Craneware trades on ~4x revenue / ~15x EBITDA, supporting our multiple assumptions.

Investment thesis

  • Platform economics finally showing through: 20% revenue growth converted into 80% adj. EBITDA growth in FY25, EBITDA margin 13→20%, on stable headcount (199→205). Management's "operating leverage inherent in the DXRX platform model" language is now backed by delivered numbers, and the FY26 guide implies another leg 2026-05 Final Results.
  • Proprietary data + entrenched customer relationships: works with 18 of the top-20 global pharma, 95 therapeutic brands (up 12%), NRR 105%, and second PMx multi-year commercialization partnership signed Q4 2025. Order book +56% to £38.9m and £21.1m of 12-month visibility de-risk FY26 2026-05 Final Results; 2026-01 FY25 trading update.
  • AI angle is real (if narrower than typical AI plays): proprietary lab/diagnostic dataset gets more valuable, not less, as pharma customers deploy agentic AI on commercial workflows; Diaceutics is both a supplier of clean, structured, labelled data and a user of AI/automation to scale delivery. Test Signal, Physician Engage / Epic EMR integration position DXRX as an execution layer for AI-driven pharma commercialisation 2026-05 Final Results — CEO review.

Key risks

  • Customer concentration and pharma budget pressure: one customer accounted for 18% of FY25 revenue (£6.6m); US = 93% of revenue. Pharma has been extending payment terms — cash conversion suffered materially in 2025 (cash £12.7m → £7.3m, -42%) despite reported profitability 2026-05 Final Results — CFO review.
  • Growth deceleration + revenue miss: constant-currency growth slowed from 39% (2024) to 24% (2025). Reported revenue £38.4m came in below the £39.0–40.2m consensus range; the EBITDA beat masked a topline miss. If FY26 guidance of 25% growth slips, both the multiple and the operating-leverage story compress simultaneously 2026-05 Final Results; 2026-01 FY25 trading update.
  • Cash cushion is thin: £7.3m cash, £2m undrawn overdraft, and rising capitalised data spend (£6.0m in 2025 vs. £4.2m in 2024). Continued working-capital stretch, M&A costs (£0.5m in 2025), or a pharma-cycle setback would force a raise. Not distressed — but not fortress-strength either 2026-05 Final Results; 2024-01 FY23 trading update.

Operating leverage

Diaceutics screens as high-operating-leverage on the evidence disclosed. FY25 gross margin was 82% (down 6pp on deliberate data investment, not price pressure); employee cost £21.1m and other admin £17.6m are largely fixed against a £38m revenue base — the 20% revenue growth in 2025 converted almost 1:1 into gross profit while opex grew only modestly, producing 80% adj. EBITDA growth. The natural incremental contribution margin on new platform revenue (Insight & Engagement Solutions grew 24% to £28.6m) is close to gross margin, i.e. ~75-85%, because delivery cost is dominated by pre-existing data assets and platform infrastructure rather than variable service labour. On this base, a 10-15% revenue upside surprise on FY26 could plausibly deliver ~£3-5m incremental EBITDA (i.e. 30-50% adj. EBITDA uplift on top of expected growth). Inflection points to watch: (i) capitalised data cost begins to plateau — management flagged this — releasing amortisation drag; (ii) the PMx model expanding to a "pipeline of 24 potential partners" would carry high incremental margins because the platform is already built; (iii) US commercial-model overhaul by Alexander Group either lifts sales productivity (operating leverage kicks harder) or adds cost without matching revenue (risk) 2026-05 Final Results — CFO/CEO review.

Value-trap signals

  • Cash down 42% YoY despite reported profitability — trade receivables +34% and accrued revenue +137%: watch working capital carefully.
  • Growth decelerating (39% → 24% CC), and FY25 revenue missed consensus.
  • 82% gross margin (down from 88%) — deliberate mix effect from non-oncology data build-out, not a structural erosion, but bears watching.
  • Customer concentration and 93% US exposure in a period of pharma budget rationalisation.

Not a value trap in classical sense (durable customer base, real IP, expanding TAM) but the "cheap on Adj. EBITDA" screen requires strong FY26 delivery to hold.

Earnings vs. expectations

  • FY22: management guided ~£16.3-16.8m revenue / £3.4-3.6m EBITDA; delivered ~£20m revenue (materially ahead) and EBITDA in-line — strong beat.
  • FY23: delivered £23.7m revenue (22% growth) in line with management's ambitious accelerated-investment expectations; broadly in-line to slight beat.
  • FY24: revenue £32.2m vs. consensus £30m (~7% beat), EBITDA marginally ahead — beat.
  • FY25: revenue £38.4m vs. consensus £39.0-40.2m (~2-4% miss), adj. EBITDA £7.6m vs. consensus £6.9-7.3m (~4-10% beat). Mixed: quality of earnings beat, topline missed.
  • Pattern: consistent revenue delivery with a modest recent-year miss on the top line but positive surprise on EBITDA/margin. Management has generally not lowered mid-year guidance.

Conviction: 3 – moderate

Anchors (support conviction): clean disclosure incl. ARR/NRR/order book; consistent 5-year growth track record with visible margin inflection; multiple valuation approaches (revenue multiple, EBITDA multiple, ARR multiple) converge around a similar range £150-190m.

Limits (caveats): FY26 case depends on 25% growth guidance holding (only Q1 datapoint at 15% CC so far); working capital and cash conversion have deteriorated and could force a raise; small-cap AIM name with limited peer set means multiple is a judgement call.

Filings consulted · 26

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-06-25Result OF Agm2026-06-25_9637030_result-of-agm.md0.30
  2. 2026-05-29Notice OF Agm Amp Posting OF Annual Report2026-05-29_9592654_notice-of-agm-amp-posting-of-annual-report.md0.95
  3. 2026-05-26Final Results2026-05-26_9583877_final-results.md1.00
  4. 2026-01-15Full Year 2025 Trading Update2026-01-15_9354456_full-year-2025-trading-update.md0.72
  5. 2025-05-21Notice OF Agm And Posting OF Annual Report2025-05-21_8890954_notice-of-agm-and-posting-of-annual-report.md0.62
  6. 2025-01-28FY 2024 Trading Update Strong Revenue Growth2025-01-28_8708291_fy-2024-trading-update-strong-revenue-growth.md0.55
  7. 2024-06-24Result OF Agm2024-06-24_8274991_result-of-agm.md0.14
  8. 2024-05-29Notice OF Agm And Posting OF Annual Report2024-05-29_8227778_notice-of-agm-and-posting-of-annual-report.md0.43
  9. 2024-05-29Notice OF Agm And Posting OF Annual Report2024-05-29_8227783_notice-of-agm-and-posting-of-annual-report.md0.43
  10. 2024-01-30Diaceutics Plc Trading Update2024-01-30_8011672_diaceutics-plc-trading-update.md0.38
  11. 2023-09-26Diaceutics Plc Half Year Results2023-09-26_7777302_diaceutics-plc-half-year-results.md0.41
  12. 2023-09-05Notice OF Interim Results And Presentations2023-09-05_7735348_notice-of-interim-results-and-presentations.md0.23
  13. 2023-07-25Trading Update And Notice OF Results2023-07-25_7652288_trading-update-and-notice-of-results.md0.21
  14. 2023-04-25Notice OF Agm And Posting OF Annual Report2023-04-25_4204_notice-of-agm-and-posting-of-annual-report.md0.24
  15. 2023-04-17Final Results2023-04-17_7491767_final-results.md0.25
  16. 2023-01-26Trading Statement And Strategy Update2023-01-26_7229209_trading-statement-and-strategy-update.md0.21
  17. 2022-09-27Half Year Report2022-09-27_7122940_half-year-report.md0.23
  18. 2022-07-26Trading Update And Notice OF Results2022-07-26_7136117_trading-update-and-notice-of-results.md0.21
  19. 2022-05-26Result OF Agm2022-05-26_7028629_result-of-agm.md0.07
  20. 2022-04-28Notice OF Agm And Posting OF Annual Report2022-04-28_7089379_notice-of-agm-and-posting-of-annual-report.md0.24
  21. 2022-03-22Notice OF 2021 Full Year Results2022-03-22_7004248_notice-of-2021-full-year-results.md0.25
  22. 2022-03-22Final Results2022-03-22_7005757_final-results.md0.25
  23. 2022-02-21Investor Presentation2022-02-21_6884990_investor-presentation.md0.17
  24. 2022-01-11Trading Update And Notice OF Results2022-01-11_6807759_trading-update-and-notice-of-results.md0.21
  25. 2021-09-14Half Year Report2021-09-14_6825487_half-year-report.md0.23
  26. 2021-08-31Notice OF Investor Presentation2021-08-31_6694352_notice-of-investor-presentation.md0.07

This research note was authored by a large language model after reading 25 regulatory filings published between 2021-08-31 and 2026-06-25. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.